Evonik Evonik

X
[{"orgOrder":0,"company":"Morningside Pharmaceuticals","sponsor":"Aspire Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"H.I.G. Capital Acquires Morningside Healthcare and Morningside Pharmaceuticals","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Morningside Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The combination will create one of the largest and fastest growing UK pharma companies and accelerated growth in current and future product portfolio, especially in healthcare (leading asset Akizza having gestodene/ethinylestradiol combination) in the UK and internationally.

            Lead Product(s): Gestodene,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Akizza

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Aspire Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 03, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY